

ASTRO School of Radiation Oncology

Online CME/SAM

Biosketch Information

Lena Specht, M.D., Ph.D.
Chief Oncologist, Associate Professor of Oncology
Copenhagen University Hospital

Brief Description of Responsibilities:

Lena Specht M.D., Ph.D., is Chief Oncologist and Associate Professor of Oncology at Copenhagen University Hospital, Denmark. Dr. Specht has been active in the research and treatment of lymphomas for many years, and has published numerous papers and textbook chapters on the subject, in particular on Hodgkin's lymphoma. She is a content editor of the Cochrane Hematological Malignancies Group, and has published several meta-analyses of randomized trials in Hodgkin's lymphoma. She is a member of the Scientific Committee of the EORTC Lymphoma Group, and an international member of the Clinical Trials Advisory and Awards Committee, Cancer Research UK. Her research group at Copenhagen University Hospital focuses on clinical research in imaging (in particular PET) and advanced radiotherapy techniques in the management of lymphomas (and other tumor types). Dr. Specht has given numerous presentations at scientific meetings worldwide; recent lectures include:

“Imaging-guided IMRT: The ‘true’ tumor.” ESTRO Teaching Course on IMRT and Other Conformal Techniques in Practice. Copenhagen 2006.

“*The new response criteria for lymphomas.*” EORTC Lymphoma Group Meeting. Brussels 2007.

“The role of PET in staging and response assessment in Hodgkin's lymphoma.” Educational Session, 12th [Unsupported Character - Codename ­] Congress of the European Hematology Association, Vienna 2007.

Educational Preparation: Copenhagen University

Internship:

Residency:

Degree: M.D., Ph.D.

Major Area of Study: Medicine

Year Earned: 1977, 1992

Select Papers:

Hutchings M, Jakobsen AL, Buhl T, Hansen M, Pedersen LM, Jurlander J, Buus S, Keiding S, Boesen AM, D'Amore F, Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. *Blood* 2006; 107: 52-9.

Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Meerwaldt J, Lievens Y, Meijnders P, Ghalibafian M, Richaud P, Carrie C, Noordijk E on behalf of the EORTC-GELA Lymphoma Group. Involved node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and recommendations. *Radiother Oncol* 2006; 79: 270-7.

Franklin J, Pluetschow A, Paus M, Specht L, Anselmo A-P, Aviles A, et al. Second malignancy risk associated with treatment for Hodgkin's lymphoma: meta-analysis of the randomized trials. *Ann Oncol* 2006; 17: 1749-60.

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol* 2007; 25: 579-86.

Specht L. 2-[18F]Fluoro-2-Deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. *Semin Radiat Oncol* 2007; 17: 190-7.